spacer
home > ebr > spring 2018 > precision healthcare
PUBLICATIONS
European Biopharmaceutical Review

Precision Healthcare

At the end of January, industry observers were brimming with speculation on the likely course of Amazon’s entry into healthcare. Championed by a corporation known for ‘disruptive innovation’ in the technology and retail sectors, this project promises to challenge the status quo in the world’s largest healthcare system that is characterised by a fragmented market, entrenched providers, dysfunctional incentives, and little consumer choice.

The manifesto of this bold project by Amazon, JP Morgan, and Berkshire- Hathaway is both challenging and modest: “Our goal is to benefit [1.2 million] US employees and their families, and potentially all Americans.” In short, the goal is to remake the market for healthcare so it becomes integrated, transparent, equitable, and more affordable. Success would not be measured by immediate financial returns, but by long-term impact. Many analysts saw the venture as the opening gambit in online retail pharmacy. This has been the buzz since Amazon acquired Whole Foods Markets last year. Consumers will derive benefit from the online utility of Amazon, as Alibaba is already proving in China.

Amazon fields best-in-class e-commerce, distribution, fulfilment, and technology. In the industry press, the mantra was ‘bricks and clicks’, but in classic economic theory, such an enterprise could upend the supply chain by disintermediation, while using its purchasing power to lower costs to consumers and achieving dominance by sheer scale and reach. Consumer costs would certainly decrease by leveraging the existing customer base and Amazon skill sets.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Emile Bellott is a member of the EBR Industry Advisory Board, a graduate of the Harvard Business School, US, a China watcher, and an industry consultant with experience in the biotechnology and biopharmaceutical industries.
spacer
Emile Bellott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

RSSL introduces same-day mycoplasma testing service in UK

Reading Scientific Services Ltd (RSSL), a leading provider of scientific and technical solutions to the global biopharmaceutical, pharmaceutical, and biopharmaceutical sectors, has introduced the United Kingdom’s first same-day mycoplasma testing service for manufacturers of biologic medicines.
More info >>

White Papers

Extractables and Leachables Testing: A Risk Based Approach

RSSL

Pharmaceutical products are in contact with many external components during both manufacture and usage and small amounts of chemicals may leach from these components with a potential health risk to the patient. Extractables and leachables (E&L) studies therefore play an important role in verifying the safety of a drug product over its lifetime. Regulatory organisations such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) are taking an increased interest in the interactions of various drug delivery devices, pharmaceutical product containers and medical devices with drug product and/or patient and this field is therefore growing in importance. Regulatory guidelines indicate that an extractables profile should be determined for all materials that contact the drug product. Once established, this profile can be used to determine whether any of these extractables are present as leachables within the product. If a leachable is detected, amounts can be determined using validated analytical methods, after which a biological risk can be established based on the exposure. This white paper will provide an overview of the processes used to determine extractables and leachables from plastics.
More info >>

 
Industry Events

PDA Europe Annual Meeting 2019

24 June 2019, Hilton Amsterdam

Featuring updates from international regulatory agencies as well as industry, this promises to become another highlight in the 2019 event calendar and is a meeting not to be missed!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement